Updated July 10, 2018 09:56:17The anti-corruption provisions of the Brianna Wu law, which was introduced in 2017, have been criticized by the pharmaceutical industry as overly restrictive and have been linked to the introduction of more than 300 generic drugs in the country.
The legislation was introduced to curb drug prices and the price of generic drugs, but some have argued that the law’s enforcement mechanisms are too weak.
“In the face of the unprecedented number of generic drug launches in the last few months, the government should take concrete steps to ensure that no new generic drug is approved or that generic drug prices are not raised,” said Shashank Rao, senior partner at law firm Latham & Bacon LLP, who has been representing pharmaceutical manufacturers.
“The government should introduce anti-corruption measures, including greater transparency and accountability for the development of new drugs, in line with our international obligations.
These measures will help to safeguard the interests of the industry and promote a healthy environment for pharmaceutical development.”
A number of companies have already agreed to abide by the law and implement the anti